The treatment, co-developed by GSK, gained approval from the U.K’s medicines regulator after a clinical trial showed a single dose slashed the risk of hospitalisation and death by 79% in high-risk adults with symptomatic infection.
The discovery highlights the uncertainty surrounding the origins of the new variant and suggests it was circulating long before being reported by South African researchers last week.
The risk was greater in younger patients and the majority died from causes not normally associated with Covid-19, the researchers said, meaning the deaths may never have been linked to coronavirus by families or doctors.
“The emergence of the highly-mutated omicron variant underlines just how perilous and precarious our situation is,” WHO’s Tedros Adhanom Ghebreyesus, adding that ending the pandemic will take more than just vaccines.
The delta variant is still responsible for over 99% of Covid-19 cases and more deaths occur in the unvaccinated, the agency’s chief scientist said Monday, after Canada identified North America’s first two omicron cases.
The European Centre for Disease Prevention and Control (ECDC) said Covid-19 boosters should be considered for all adults and could help relieve the pressure from the virus over winter.
Covid-19 is now the leading cause of death in Europe, the WHO said, as countries introduce tough new restrictions, introduce mandatory vaccination and reenter lockdown to control the surge.